Pharmacokinetics of Cisatracurium in Patients Receiving Nitrous Oxide/Opioid/Barbiturate Anesthesia
- 1 February 1996
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 84 (2) , 300-308.
- https://doi.org/10.1097/00000542-199602000-00007
Abstract
Background: Cisatracurium, one of the ten isomers in atracurium, is a nondepolarizing muscle relaxant with an intermediate duration of action. It is more potent and less likely to release histamine than atracurium. As one of the isomers composing atracurium, it presumably undergoes Hofmann elimination. This study was conducted to describe the pharmacokinetics of cisatracurium and its metabolites and to determine the dose proportionality of cisatracurium after administration of 2 or 4 times the ED(95). Methods: Twenty ASA physical status 1 or 2 patients undergoing elective surgery under nitrous oxide/opioid/barbiturate anesthesia were studied. Patients received a single rapid intravenous bolus does of 0.1 or 0.2 mg x kg-1 (2 or 4 times the ED(95), respectively) cisatracurium. All patients were allowed to recover spontaneously to a train-of-four ratio > or = 0.70 after cisatracurium-induced neuromuscular block. Plasma was extracted, acidified, and stored frozen before analysis for cisatracurium, laudanosine, the monoquaternary acid, and the monoquaternary alcohol metabolite. Results: The clearances (5.28 +/- 1.23 vs. 4.66 +/- 0.67 ml x min(-1) x kg(-1) and terminal elimination half-lives (22.4 +/- 2.7 vs. 25.5 +/- 4.1 min) were not statistically different between patients receiving 0.1 mg x kg(-1) and 0.2 mg x kg(-1), respectively. Maximum concentration values for laudanosine averaged 38 +/- 21 and 103 +/- 34 ng x ml(-1) for patients receiving the 0.1 and 0.2 mg x kg(-1) doses, respectively. Maximum concentration values for monoquaternary alcohol averaged 101 +/- 27 and 253 +/- 51 ng x ml(-1), respectively. Monoquaternary acid was not quantified in any plasma sample. Conclusions: Cisatracurium undergoes Hofmann elimination to form laudanosine. The pharmacokinetics of cisatracurium are independent of dose after single intravenous doses of 0.1 and 0.2 mg x kg(-1).Keywords
This publication has 20 references indexed in Scilit:
- The in vitro degradation of cisatracurium, the R, cis-R′-isomer of atracurium, in human and rat plasmaClinical Pharmacology & Therapeutics, 1995
- The Clinical Neuromuscular Pharmacology of 51W89 in Patients Receiving Nitrous Oxide/Opioid/Barbiturate AnesthesiaAnesthesiology, 1995
- Succinylcholine Increases Intraocular Pressure in the Human Eye with the Extraocular Muscles DetachedAnesthesiology, 1993
- Distribution, Elimination, and Action of Vecuronium in the ElderlyAnesthesia & Analgesia, 1991
- PHARMACOKINETICS OF ATRACURIUM AND LAUDANOSINE IN PATIENTS WITH HEPATIC CIRRHOSISBritish Journal of Anaesthesia, 1989
- General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartmentJournal of Pharmacokinetics and Biopharmaceutics, 1988
- The Pharmacodynamics and Pharmacokinetics of Vecuronium in Patients Anesthetized with Isoflurane with Normal Renal Function or with Renal FailureAnesthesiology, 1988
- The Pharmacokinetics and Pharmacodynamics of Atracurium in Patients with and without Renal FailureAnesthesiology, 1984
- PHARMACOKINETICS OF ATRACURIUM BESYLATE IN HEALTHY PATIENTS (AFTER A SINGLE I.V. BOLUS DOSE)British Journal of Anaesthesia, 1983
- INSRIRED OXYGEN AND OXYGEN TRANSFER DURING ARTIFICIAL VENTILATION FOR RESPIRATORY FAILUREBritish Journal of Anaesthesia, 1983